These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36477830)

  • 1. Psychedelic Drug Legislative Reform and Legalization in the US.
    Siegel JS; Daily JE; Perry DA; Nicol GE
    JAMA Psychiatry; 2023 Jan; 80(1):77-83. PubMed ID: 36477830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
    Jones G; Arias D; Nock M
    Sci Rep; 2022 Dec; 12(1):21927. PubMed ID: 36535992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca].
    Szabó A; Kazai A; Frecska E; Brys Z
    Neuropsychopharmacol Hung; 2015 Sep; 17(3):120-8. PubMed ID: 26485742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.
    Thomas KL; Jesse R; Mehtani NJ; Mitchell JM; Anderson BT
    J Psychoactive Drugs; 2024; 56(2):206-210. PubMed ID: 37061961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
    Johnston CB; Mangini M; Grob C; Anderson B
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):44-53. PubMed ID: 36184377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):46-56. PubMed ID: 34983249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):66-73. PubMed ID: 35090364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
    Siegel AN; Meshkat S; Benitah K; Lipsitz O; Gill H; Lui LMW; Teopiz KM; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 Jul; 139():71-81. PubMed ID: 34048997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.
    Jones G; Lipson J; Wang E
    Sci Rep; 2023 Feb; 13(1):2466. PubMed ID: 36774449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
    Bender D; Hellerstein DJ
    Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.